SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Read more about SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Read more about Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study.
Lack of toxicity of a STAT3 decoy oligonucleotide. Read more about Lack of toxicity of a STAT3 decoy oligonucleotide.
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Read more about A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Read more about Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Read more about Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Key research issues in the management of hepatocellular carcinoma. Read more about Key research issues in the management of hepatocellular carcinoma.
Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. Read more about Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil.
Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Read more about Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.
Elevated plasma tamoxifen levels in a patient with liver obstruction. Read more about Elevated plasma tamoxifen levels in a patient with liver obstruction.
